Press release
Thyroid Cancer Treatment Market 2032: Clinical Trials, Medication, Prevalence, Statistics, Revenue, Therapies, EMA, PDMA, FDA Approvals, and Companies by DelveInsight
(Albany, USA) DelveInsight's "Thyroid Cancer Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Thyroid Cancer, historical and forecasted epidemiology as well as the Thyroid Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.Discover which therapies are expected to grab the Thyroid Cancer Market Share @ Thyroid Cancer Market Outlook- https://www.delveinsight.com/sample-request/thyroid-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Key Takeaways from the Thyroid Cancer Market Report
• In March 2025, Sanofi announced a study is to give patients with medullary thyroid cancer either 300mg/day or 150mg/day vandetanib and compare how well each dose affects how their cancer responds. It will also help the investigators understand the side effects of different doses in these patients.
• In March 2025, Genzyme, a Sanofi Company organized a study is to learn how hereditary or sporadic medullary thyroid cancer patients, treated with ZD6474, react to the drug, what happens to ZD6474 in the human body, about the side effects of ZD6474, and if ZD6474 can decrease or prevent the growth of tumors.
• The increase in Thyroid Cancer Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
• As per DelveInsight analysis, the Thyroid Cancer Market is anticipated to witness growth at a considerable CAGR.
• As per Surveillance, Epidemiology, and End Results (SEER), Thyroid cancer accounts for 43,800 new cases in the US, in 2022.
• As per a study by The American Cancer Society (2022), the most recent estimates for thyroid cancer in the United States are about 43,800 new cases of thyroid cancer accounting for 11,860 cases in men and 31,940 cases in women.
• The leading Thyroid Cancer Companies such as Suzhou Zelgen Biopharmaceuticals, Jiangsu Chia-Tai Tianqing Pharmaceutical, Takeda, Bristol-Myers Squibb, Genentech, AffyImmune Therapeutics, Inc., Taizhou Hanzhong biomedical co. LTD, NantCell, Bayer, Merck Sharp & Dohme Corp., Pfizer, MedImmune LLC, Eisai Inc., cCAM Biotherapeutics, Purple Biotech Ltd., Turning Point Therapeutics, Inc., Hoffmann-La Roche and others.
• Promising Thyroid Cancer Pipeline Therapies such as Lenalidomide, Sorafenib (Nexavar, BAY43-9006), Lenvatinib, Vandetanib, Surufatinib and others.
Stay ahead in the Thyroid Cancer Therapeutics Market with DelveInsight's Strategic Report @ Thyroid Cancer Market Outlook- https://www.delveinsight.com/sample-request/thyroid-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Thyroid Cancer Epidemiology Segmentation in the 7MM
The epidemiology section of Thyroid Cancer offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.
• Total Thyroid Cancer Incident Cases
• Thyroid Cancer Age-specific cases
• Thyroid Cancer Gender-specific Cases
• Thyroid Cancer Stage-specific incident cases
• Thyroid Cancer Type-specific incident cases
• Total Thyroid Cancer Treated Cases
Download the report to understand which factors are driving Thyroid Cancer Epidemiology trends @ Thyroid Cancer Prevalence- https://www.delveinsight.com/sample-request/thyroid-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Emerging Thyroid Cancer Drugs
• Donafenib: Suzhou Zelgen Biopharmaceuticals
Donafenib, an orally administered multikinase inhibitor, is being developed by Suzhou Zelgen Biopharmaceuticals for the treatment of Late stage cancers. The product targets Raf kinase and various receptor tyrosine kinases (RTKs), with potential antineoplastic activity. Currently, it is in phase 3 of development stage for the treatment of thyroid cancer.
• Anlotinib: Jiangsu Chia-Tai Tianqing Pharmaceutical
Anlotinib is an orally administered tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptors (PDGFR), and c-kit. Currently, it is in phase 3 of development stage for the treatment of thyroid cancer.
• Nivolumab: Bristol-Myers Squibb
Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. Currently, it is in phase 2 of development stage for the treatment of thyroid cancer.
Thyroid Cancer Drugs Market
The Thyroid Cancer Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Thyroid Cancer signaling in Thyroid Cancer are likely to uncover new therapeutic targets and further expand treatment options for patients.
Thyroid Cancer Treatment Market Landscape
The Thyroid Cancer treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Thyroid Cancer has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.
To learn more about Thyroid Cancer treatment guidelines, visit @ Thyroid Cancer Treatment Market Landscape- https://www.delveinsight.com/sample-request/thyroid-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Thyroid Cancer Market Outlook
The report's outlook on the Thyroid Cancer market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Thyroid Cancer therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Thyroid Cancer drug and late-stage pipeline therapy.
Thyroid Cancer Drugs Uptake
The drug chapter of the Thyroid Cancer report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Thyroid Cancer.
Major Thyroid Cancer Companies
Suzhou Zelgen Biopharmaceuticals, Jiangsu Chia-Tai Tianqing Pharmaceutical, Takeda, Bristol-Myers Squibb, Genentech, AffyImmune Therapeutics, Inc., Taizhou Hanzhong biomedical co. LTD, NantCell, Bayer, Merck Sharp & Dohme Corp., Pfizer, MedImmune LLC, Eisai Inc., cCAM Biotherapeutics, Purple Biotech Ltd., Turning Point Therapeutics, Inc., Hoffmann-La Roche and others.
Learn more about the FDA-approved drugs for Thyroid Cancer @ Drugs for Thyroid Cancer Treatment- https://www.delveinsight.com/sample-request/thyroid-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the Thyroid Cancer Market Report
• Coverage- 7MM
• Study Period- 2019-2032
• Thyroid Cancer Companies- Suzhou Zelgen Biopharmaceuticals, Jiangsu Chia-Tai Tianqing Pharmaceutical, Takeda, Bristol-Myers Squibb, Genentech, AffyImmune Therapeutics, Inc., Taizhou Hanzhong biomedical co. LTD, NantCell, Bayer, Merck Sharp & Dohme Corp., Pfizer, MedImmune LLC, Eisai Inc., cCAM Biotherapeutics, Purple Biotech Ltd., Turning Point Therapeutics, Inc., Hoffmann-La Roche and others.
Thyroid Cancer Pipeline Therapies- Lenalidomide, Sorafenib (Nexavar,BAY43-9006), Lenvatinib, Vandetanib, Surufatinib and others.
• Thyroid Cancer Market Dynamics: Thyroid Cancer Market Drivers and Barriers
• Thyroid Cancer Market Access and Reimbursement, Unmet Needs and Future Perspectives
Discover more about Thyroid Cancer Drugs in development @ Thyroid Cancer Clinical Trials Assessment- https://www.delveinsight.com/sample-request/thyroid-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Content
1. Key Insights
2. Thyroid Cancer Executive Summary
3. Thyroid Cancer Competitive Intelligence Analysis
4. Thyroid Cancer: Market Overview at a Glance
5. Thyroid Cancer: Disease Background and Overview
6. Patient Journey
7. Thyroid Cancer Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Thyroid Cancer Unmet Needs
10. Key Endpoints of Thyroid Cancer Treatment
11. Thyroid Cancer Marketed Products
12. Thyroid Cancer Emerging Therapies
13. Thyroid Cancer: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Thyroid Cancer Market Outlook
16. Access and Reimbursement Overview of Thyroid Cancer
17. KOL Views
18. Thyroid Cancer Market Drivers
19. Thyroid Cancer Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Trending Reports:
• Angina Pectoris Market: https://www.delveinsight.com/report-store/angina-angina-pectoris-market
• Anorectal Malformation Market: https://www.delveinsight.com/report-store/anorectal-malformation-market
• Anovulation Market: https://www.delveinsight.com/report-store/anovulation-market
• Anterior Cruciate Ligament Injuries Market: https://www.delveinsight.com/report-store/anterior-cruciate-ligament-injuries-epidemiology-forecast
• Antibody Mediated Rejection Market: https://www.delveinsight.com/report-store/antibody-mediated-rejection-market
• Antiphospholipid Syndrome Aps Market: https://www.delveinsight.com/report-store/antiphospholipid-syndrome-aps-market
• Arthroscopic Shavers Market: https://www.delveinsight.com/report-store/arthroscopic-shavers-market
• Arthroscopy Devices Market: https://www.delveinsight.com/report-store/arthroscopy-devices-market
• Artificial Kidney Market: https://www.delveinsight.com/report-store/artificial-kidney-market
• Aspergillosis Market: https://www.delveinsight.com/report-store/aspergillosis-market
• Atherectomy Devices Market: https://www.delveinsight.com/report-store/atherectomy-devices-market
• Atypical Teratoid Rhabdoid Tumors Market: https://www.delveinsight.com/report-store/atypical-teratoid-rhabdoid-tumors-market
• Hyperhidrosis Market: https://www.delveinsight.com/report-store/axillary-hyperhidrosis-ahh-market
• Bacterial Pyogenic Meningitis Market: https://www.delveinsight.com/report-store/bacterial-pyogenic-meningitis-market
• Becker Muscular Dystrophy Market: https://www.delveinsight.com/report-store/becker-muscular-dystrophy-market
• Bile Duct Neoplasm Market: https://www.delveinsight.com/report-store/bile-duct-cancer-market
• Bipolar Depression Market: https://www.delveinsight.com/report-store/bipolar-disorder-manic-depression-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Bradycardia Treatment Devices Market: https://www.delveinsight.com/report-store/bradycardia-treatment-devices-market
• Bronchopulmonary Dysplasia Market: https://www.delveinsight.com/report-store/bronchopulmonary-dysplasia-market
• Bunion Market: https://www.delveinsight.com/report-store/bunion-market
• Cancer Anorexia Market: https://www.delveinsight.com/report-store/cancer-anorexia-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Cardiotoxicity Market: https://www.delveinsight.com/report-store/cardiotoxicity-market
• Carpal Tunnel Syndrome Market: https://www.delveinsight.com/report-store/carpal-tunnel-release-system-market
• Catheter-related Bloodstream Infections Market: https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-crbsi-market-size-analysis
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Thyroid Cancer Treatment Market 2032: Clinical Trials, Medication, Prevalence, Statistics, Revenue, Therapies, EMA, PDMA, FDA Approvals, and Companies by DelveInsight here
News-ID: 3952207 • Views: …
More Releases from DelveInsight Business Research

Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals.
Objective of the Case Study
The…

Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics.
According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than…

Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies.
Biopsy devices play a crucial role in disease diagnosis by…

Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide.
DelveInsight's General Surgery Devices Market Report 2032 provides…
More Releases for Cancer
Cancer Therapeutics Market New Business Opportunities to Hit $180.19 billion by …
Surge in geriatric population and rise in the number of collaborations & partnerships to facilitate drug development are the key drivers of the global cancer therapeutics market. In addition, heavy inflow of investment in R&D activities has enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence boost the market. The high demand for personalized medicine along with high potential of emerging…
Global Cancer Diagnostics Market Size, Trends & Growth Opportunity By Applicatio …
Cancer diagnostics is a process of detecting various proteins, biomarkers and certain symptoms that result in the detection of presence of cancerous tumour in patients. Detection of certain proteins and biomarkers which are prevalent in cancer disorder thereby results in diagnosis process. Cancer diagnostics includes usage of certain technology and devices for detection purpose.
Increase in incidence of target diseases like cancer is key driving factor which is expected to boost…
2019-2027 Oncology Nutrition Market is driven by Major Cancer Type - Head and Ne …
The "Global Oncology Nutrition Market Analysis to 2027" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of oncology nutrition market with detailed market segmentation by cancer type and geography. The global oncology nutrition market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the…
Cancer Immunotherapy Market 2018 To 2025 - SWOT Analysis By Global Industry Reve …
The Cancer Immunotherapy Market research report provided by Crystal Market Research (CMR) is the most detailed study about Cancer Immunotherapy Market that is estimated to grow at a tremendous rate over the forecast period 2018-2025. This report contains precise and updated insights in respect with the leading market players and prevailing regions of the business.
Cancer Immunotherapy Market By Product and Cancer Type - Global Industry Analysis And Forecast To 2025:…
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance …
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine.
These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch…
Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung …
Researchmoz added Most up-to-date research on "Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung Cancer, Kidney Cancer, Bone Cancer, Breast Cancer, Prostate Cancer, And Others" to its huge collection of research reports.
Tumor ablation is the removal of the tumor cells or tissue with minimally invasive procedure. Tumor ablation devices are consists of an applicator (catheter), which is introduced into the tumor under imaging guidance. For…